22nd Century Group, Inc. (XXII)

CDC Survey Finds Most U.S. Adults, including 80% of Smokers, Favor Lowering Nicotine Levels in Cigarettes to Make Them Less Addictive

Studies show that FDA enjoys broad consumer support to dramatically lower nicotine in cigarettes

News Release – July 12, 2019

View Press Release

22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics

News Release – April 09, 2019

View Press Release

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States

News Release – December 23, 2019

View Press Release

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

FDA determines that sale of product in the U.S. is ‘appropriate for the protection of the public health

News Release – December 17, 2019

View Press Release

22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs

News Release – December 03, 2019

View Press Release

Company Mission & Profile

22nd Century Group is a plant biotechnology company focused on reducing nicotine in tobacco and creating new hemp/cannabis plants

About Us

22nd Century Group’s FDA Advisory Committee Meeting for Reduced Nicotine Content Cigarettes Brings New Standard for the Tobacco Industry

View Press Release View All

Jan 13, 2020 • 6:45 AM EST

22nd Century Group Appoints New Director and New Chairman

View Press Release

Dec 23, 2019 • 3:39 PM EST

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

View Press Release

Dec 17, 2019 • 1:34 PM EST

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

View Press Release

February 14, 2020

Reduced-Nicotine Smokes May Be Arriving to the U.S. Shortly

View Media Release

November 8, 2019

Webcast: Third Quarter Business Update

View Media Release

July 31, 2018

The urgent case for nonaddictive cigarettes

View Media Release

View All Media

CDC Survey Finds Most U.S. Adults, including 80% of Smokers, Favor Lowering Nicotine Levels in Cigarettes to Make Them Less Addictive

Studies show that FDA enjoys broad consumer support to dramatically lower nicotine in cigarettes

22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

FDA determines that sale of product in the U.S. is ‘appropriate for the protection of the public health

22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs

Company Mission & Profile

22nd Century Group is a plant biotechnology company focused on reducing nicotine in tobacco and creating new hemp/cannabis plants

Latest News

22nd Century Group’s FDA Advisory Committee Meeting for Reduced Nicotine Content Cigarettes Brings New Standard for the Tobacco Industry

22nd Century Group Appoints New Director and New Chairman

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

Latest Media

Reduced-Nicotine Smokes May Be Arriving to the U.S. Shortly

Webcast: Third Quarter Business Update

The urgent case for nonaddictive cigarettes

CDC Survey Finds Most U.S. Adults, including 80% of Smokers, Favor Lowering Nicotine Levels in Cigarettes to Make Them Less Addictive

Studies show that FDA enjoys broad consumer support to dramatically lower nicotine in cigarettes

22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

FDA determines that sale of product in the U.S. is ‘appropriate for the protection of the public health

22nd Century Group Enters CBD Health and Wellness Market with Investment in Panacea Life Sciences, Inc.

Investment provides platform to commercialize 22nd Century’s unique hemp/cannabis plant lines in development and leverage strengths in consumer-packaged-goods and FDA-regulatory affairs

Company Mission & Profile

22nd Century Group is a plant biotechnology company focused on reducing nicotine in tobacco and creating new hemp/cannabis plants

Email Alerts

Latest News

22nd Century Group’s FDA Advisory Committee Meeting for Reduced Nicotine Content Cigarettes Brings New Standard for the Tobacco Industry

22nd Century Group Appoints New Director and New Chairman

22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee

FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes

Latest Media

Reduced-Nicotine Smokes May Be Arriving to the U.S. Shortly

Webcast: Third Quarter Business Update

The urgent case for nonaddictive cigarettes